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Abstract 12 
The Gram negative human pathogen Pseudomonas aeruginosa is able to tolerate high 13 
concentrations of β-lactam antibiotics. Despite inhibiting the growth of the organism, these cell 14 
wall-targeting drugs exhibit remarkably little bactericidal activity. However, the mechanisms 15 
underlying β-lactam tolerance are currently unclear. Here we show that P. aeruginosa undergoes 16 
a rapid en masse transition from normal rod shaped cells to viable, cell wall defective spherical 17 
cells when treated with β-lactams from the widely used carbapenem and penicillin classes. When 18 
the antibiotic is removed, the entire population of spherical cells quickly converts back to the 19 
normal bacillary form. Our results demonstrate that these rapid population-wide cell morphotype 20 
transitions function as a strategy to survive antibiotic exposure. Taking advantage of these 21 
findings, we have developed a novel approach to efficiently kill P. aeruginosa by using 22 
carbapenem treatment to induce en masse transition to the spherical cell morphotype and then 23 
exploiting the relative fragility and sensitivity of these cells to killing by antimicrobial peptides 24 
(AMPs) that are relatively inactive against P. aeruginosa bacillary cells. This approach could 25 
broaden the repertoire of antimicrobial compounds used to treat P. aeruginosa and serve as a 26 
basis for developing new therapeutics to combat bacterial infections. 27 
28 
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Introduction 29 
Pseudomonas aeruginosa is a major human pathogen and a leading cause of hospital-acquired 30 
infections. P. aeruginosa infections are difficult to eradicate and are often fatal, which is in part 31 
due to the organism’s high intrinsic resistance to a variety of different antimicrobials (1). The 32 
mechanisms underlying intrinsic antibiotic resistance in P. aeruginosa are largely well 33 
understood. However, an important and as yet unexplained observation is the ability of P. 34 
aeruginosa to survive in the presence of high concentrations of the cell wall-targeting β-lactam 35 
antibiotics. 36 
 37 
β-lactams are a broad class of antibiotics that include penicillin derivatives, cephalosporins, 38 
monobactams, and carbapenems. They are the most widely used group of antibiotics in the world 39 
(2) and mediate bacterial killing primarily by inhibiting the enzymes, known as penicillin-binding 40 
proteins or PBPs, that catalyse the formation of peptidoglycan cross-links in the bacterial cell 41 
wall (3). β-lactams drugs typically exhibit bactericidal activity against susceptible organisms (4), 42 
and this is often associated with changes in bacterial morphology and the formation of spherical 43 
or filamentous cells that are prone to lysis (3, 5-8).  44 
 45 
Interestingly, despite inhibiting cell growth, β-lactams have been found to have very little 46 
bactericidal activity against P. aeruginosa (9-13). This intrinsic tolerance of β-lactams likely 47 
accounts for the fact that when treating P. aeruginosa infections, optimal microbiological 48 
outcomes occur when β-lactam concentrations are maintained at 4-6.6 x the minimal inhibitory 49 
concentration (MIC) throughout the majority of the dosing period (13). Furthermore, β-lactam 50 
tolerance by P. aeruginosa can lead to the emergence of spontaneous β-lactam resistant strains 51 
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(12, 14). Thus β-lactam tolerance provides significant challenges for clinicians when treating P. 52 
aeruginosa infections. The mechanisms underlying this tolerance, however, are unclear.  53 
 54 
Here we show that tolerance of P. aeruginosa to several β-lactams, including carbapenems and a 55 
penicillin derivative, is mediated by a rapid population-wide transition to a viable, cell wall 56 
defective spherical form. We demonstrate that these spherical cells can survive in the presence of 57 
antibiotic and quickly revert to the normal bacillary mode of growth following its removal. Our 58 
results indicate that transition to the spherical cell morphotype likely does not require the 59 
acquisition of specific mutations but rather is an intrinsic response to antibiotic exposure that 60 
serves as a survival strategy. Significantly, we further demonstrate that P. aeruginosa can be 61 
efficiently killed by combining the β-lactam meropenem with antimicrobial peptides that show 62 
little to no activity against bacillary cells of P. aeruginosa. We propose that such combination 63 
treatments could provide a novel approach for antibacterial therapy.  64 
 65 
Materials and Methods 66 
Bacterial strains, media and growth conditions 67 
P. aeruginosa strains used in this study were PA14, PAO1, PA103, PAK, ATCC27853, PAE27 68 
(otitis externa isolate, Gribbles Pathology, Melbourne, Australia) and PA911 (cystic fibrosis lung 69 
isolate, Monash Medical Centre, Melbourne, Australia). All experiments were performed with 70 
strain PA14 unless otherwise indicated.  Cells were grown either in cation-adjusted Mueller 71 
Hinton broth (CAMHB; Fig. 1), synthetic cystic fibrosis sputum medium (15) (Fig. S1A), fetal 72 
bovine serum (Fig. S1B) or CAMHB supplemented with 0.5 M sucrose (Fig. 2-7 and Fig. S2-S3). 73 
To induce spherical cell formation, cultures were grown to early-exponential phase at 37°C with 74 
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vigorous shaking, antibiotic was added and cells were then incubated without shaking at 37°C. 75 
For reversion, spherical cells were pelleted by centrifugation at 3,000 g for 10 min, resuspended 76 
in antibiotic-free media and grown with static incubation at 37°C. Antibiotics were used at 5x 77 
MIC, as determined against strain PA14 using standard methods (16). MIC values for PA14 were 78 
as follows: meropenem, 1 μg/mL; imipenem, 2 μg/mL; carbenicillin, 128 μg/mL. MIC values for 79 
meropenem were also determined against each strain used in the study and were found to be 80 
between 1-2 μg/mL for all strains.  81 
 82 
Phase-contrast and fluorescence microscopy 83 
To prepare samples for phase-contrast imaging, a 1.0 X 1.0 cm square well was set up on the 84 
surface of a glass microscope slide by attaching a 25 μL Gene Frame (ABgene). The well was 85 
filled with 25 μL of culture and a coverslip was placed on top. For fluorescence microscopy 86 
(live/dead staining and super resolution 3D-SIM), 200 μL of cells were applied to a 35 mm sterile 87 
glass bottom FluoroDish (World Precision Instruments). Membrane stain FM1-43FX (5 μg/mL; 88 
Life Technologies) was added to the sample before applying to the dish for 3D-SIM. Syto9 (5 89 
M; Life Technologies) and propidium iodide (30 M; BD) were added for live/dead staining.  90 
 91 
An Olympus IX71 wide-field inverted microscope was used for phase-contrast imaging, a Zeiss 92 
Axioplan 2 fluorescence microscope was used for imaging of live/dead stained cells and a 93 
DeltaVision OMX-Blaze™ (Applied Precision Inc.) was used for 3D-SIM (17). Images were 94 
processed as described previously (17), analysed and presented using AnalySIS Research Pro 95 
(Olympus), AxioVision (Zeiss) or IMARIS (Bitplane) software.  96 
 97 
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Transmission electron microscopy (TEM) 98 
To prepare samples for TEM, cells were pelleted by centrifugation at 3,000 g for 10 min and 99 
resuspended in a fixative solution of 2% glutaraldehyde in phosphate buffered saline (PBS; 0.1M, 100 
pH 7.2) containing 0.1 M sucrose. Cells were fixed overnight at 4°C, then washed three times in 101 
PBS. Cell pellets were embedded in 1% low melt agarose (J.T. Baker Inc.) and agarose blocks 102 
were cut into 1 mm cubes, transferred to glass vials and post-fixed in 1% osmium tetroxide 103 
(OSO4) in PBS for 1 h at room temperature. Following post-fixation, samples were washed in 104 
distilled water three times for 5 min each wash and immersed in 2% aqueous uranyl acetate for 105 
30 min. Cell pellets were dehydrated through a graded series of ethanols (50-100%), infiltrated 106 
and subsequently embedded in L. R. White Resin (London White Resin Company). Ultra-thin 107 
(70 nm) sections were cut using a Reichert ultramicrotome (Ultracut S, Leica Microsystems) and 108 
mounted onto pioloform-coated, 300 mesh, thin-bar copper grids. Grids were stained with 109 
saturated aqueous uranyl acetate (7.7%) for 30 min and Reynold’s lead citrate for 4 min. Samples 110 
were examined using a Philips CM0 transmission electron microscope equipped with a 111 
Megaview III TEM CCD camera and iTEM image capture software (Olympus). Digital images 112 
were processed for publication using Adobe Photoshop CS version 8.0 (Adobe Systems). All 113 
TEM materials were supplied from ProScitech, Australia. 114 
 115 
Viability assays 116 
To estimate the number of viable cells in culture, 10-fold dilutions were plated in triplicate onto 117 
LB medium containing 1.6% agar (without antibiotics) and incubated overnight at 37°C. 118 
Colonies were counted and viability was calculated as the number of colony forming units 119 
(CFUs) per mL of culture. 120 
 121 
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Results 122 
P. aeruginosa cells rapidly convert to a viable spherical morphotype when treated with 123 
meropenem 124 
As an initial approach to understand β-lactam tolerance by P. aeruginosa, we monitored P. 125 
aeruginosa cells under the microscope following treatment with meropenem, a broad-spectrum 126 
carbapenem antibiotic that is commonly used to treat P. aeruginosa infections in humans. It has 127 
been noted in previous studies that P. aeruginosa cells switch to a spherical morphology when 128 
exposed to meropenem (7, 8). We hypothesized that this spherical morphotype may be a viable 129 
alternative form of the bacterium that mediates survival in the presence of the antibiotic.  130 
 131 
 To test this, P. aeruginosa strain PA14 was first cultured in a standard laboratory growth 132 
medium (cation-adjusted Mueller Hinton broth) and treated with a clinically relevant dose of 133 
meropenem (5x MIC). Cells were then visualized at regular intervals using conventional phase-134 
contrast microscopy. In the presence of meropenem, we observed a rapid and efficient conversion 135 
of the entire population from normal rod shaped cells to apparently spherical cells (Fig. 1A-E). 136 
Just 1 h after the addition of the antibiotic a large proportion of cells (65%) had clearly begun 137 
transitioning to the spherical morphology. Most cells (67%) had completed the transition by 4 h, 138 
and after 24 h the entire population consisted only of spherical cells (Fig. 1E). To determine if 139 
these spherical cells were viable we co-stained PA14 with the fluorescent dyes Syto9 and 140 
propidium iodide after 24 h exposure to meropenem. This approach differentiates viable cells, 141 
which only stain with Syto9 (green), from dead cells that also stain with propidium iodide (red) 142 
(Fig. 1F, G). These assays showed that the vast majority of spherical cells in the population 143 
(84%) were viable and thus able to tolerate exposure to 5x MIC of the antibiotic.  144 
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 145 
The remaining 16% of cells were lysed, and could be distinguished from viable cells not only by 146 
live/dead staining but also by a characteristic “ghost”-like appearance in phase-contrast images 147 
(Fig. 1F, arrow). Interestingly, we found that the addition of 0.5M sucrose to the growth medium 148 
as an osmoprotectant reduced the number of lysed cells from 16% to 3% after 24 h exposure to 149 
meropenem (Fig. 1H, I). Osmoprotection was clearly not essential for spherical cell formation or 150 
viability, however, unless otherwise indicated, we chose to add 0.5M sucrose to the growth 151 
medium in subsequent experiments (Fig. 2-7) simply to minimize the small amount of cell lysis 152 
observed in standard laboratory broth. 153 
 154 
Importantly, we also tested whether spherical cells can form under conditions relevant to 155 
infection and the in vivo environment. To this end PA14 cells were treated with meropenem (5x 156 
MIC) in a synthetic sputum medium designed to mimic the cystic fibrosis lung (15), as well as in 157 
fetal bovine serum. Note, sucrose was not added to these media. In both synthetic sputum and 158 
fetal bofine serum we observed a rapid transition of the cellular population from rods to spherical 159 
cells following treatment with meropenem, similar to that seen in standard growth media (Fig. 160 
S1). Therefore, P. aeruginosa spherical cells form in response to meropenem exposure under 161 
physiologically relevant conditions. 162 
 163 
To confirm the spherical shape of meropenem-treated cells we used 3D-structured illumination 164 
microscopy (3D-SIM), a super resolution fluorescence technique that enables genuine 3D images 165 
of bacterial cells and reveals morphological details not visible with conventional microscopy 166 
through increases in both lateral and axial resolution (18) (Fig. 2). We also used 3D-SIM to 167 
examine the transition from rod to sphere, and found that it begins with the emergence of a small 168 
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membrane protrusion on the cell surface (Fig. 2B). This gradually bulges out to form a larger 169 
sphere, which becomes completely enclosed in its own membrane. The original rod then lyses, 170 
leaving a mature, spherical cell (Fig. 2B, C).  171 
 172 
P. aeruginosa spherical cells have a defective cell wall and disrupted outer membrane 173 
The bacterial cell wall is a key structural feature of the cell that determines its shape and serves as 174 
an important osmotic barrier to the external environment. The loss of cell shape observed after 175 
meropenem treatment of P. aeruginosa, together with the slight osmosensitivity of the resulting 176 
spherical cells (see above), strongly suggests that these cells lack a functional cell wall. In 177 
addition, we found that spherical cells rapidly burst when placed directly between a microscope 178 
slide and a coverslip, indicating a mechanical fragility consistent with loss of integrity in the cell 179 
envelope.  180 
 181 
To further examine the cell envelope structure of the spherical cell morphotype, we performed 182 
transmission electron microscopy (TEM) on thin sections of PA14 cells after 24 h exposure to 183 
meropenem. We also examined untreated cells as a control, and as expected these cells exhibited 184 
a regular double membrane cell envelope structure characteristic of Gram negative bacteria (Fig. 185 
3A, B). In spherical cells, however, the outer membrane was clearly disrupted in all cells 186 
examined (Fig. 3C, D; 82 cells were analysed in total). While fragments of outer membrane 187 
remained associated with the cell (Fig. 3C), there were extensive regions in which the inner 188 
membrane appeared to be exposed on the cell surface. Interestingly, membrane vesicles were 189 
often observed to form apparently from outer membrane material that had detached from the cell 190 
envelope (Fig. 3C, D). Taken together, these results indicate that P. aeruginosa cells can convert 191 
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to an alternative form deficient in an intact cell wall and outer membrane when challenged with a 192 
cell wall-targeting antibiotic.  193 
 194 
The transition to spherical cells is readily reversible 195 
To test whether P. aeruginosa PA14 spherical cells induced by meropenem treatment can revert 196 
to normal rod shaped cells in the absence of antibiotic selection, we resuspended spherical cells 197 
formed after 24 h exposure to meropenem in fresh media lacking the drug. Cells were then 198 
visualized at regular intervals by phase-contrast microscopy and 3D-SIM. Under these 199 
conditions, we observed a rapid population-wide transition of the cellular population from 200 
spherical cells back to normal bacillary cells (Fig. 4). The first visible sign of this reversion was a 201 
change from a spherical to an ellipsoid morphology, which could be seen in some cells after just 202 
30 min in the absence of drug. This was followed by a gradual elongation in cell length and 203 
reduction in width to produce a normal cylindrical cell. High resolution 3D-SIM images showed 204 
that the cell surface was highly irregular, sometimes even branched, during this reversion 205 
process, but ultimately became smooth and uniform as the normal cell wall was restored (Fig. 206 
4E). After 6 h in the absence of antibiotic, the vast majority of the cellular population (>90%) had 207 
completed the transition to rods (Fig. 4F). These cells were able to grow and divide normally, as 208 
evidenced by a rapid increase in the density of cells in culture following reversion to the rod 209 
shape (Fig. 4C-D). This indicates that the transition to spherical cells following exposure to 210 
meropenem is readily reversible. 211 
 212 
Spherical cell formation is a conserved mechanism of meropenem tolerance 213 
Importantly, we observed that the ability to transition into and out of the spherical cell state 214 
occurred independently of strain background. An identical response to meropenem treatment was 215 
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seen for a wide variety of P. aeruginosa strains, including well known lab strains (PA14, PAO1, 216 
PA103, PAK, ATCC27853) and recent clinical isolates (data not shown). This observation, along 217 
with the sheer speed, efficiency and reversibility of the rod to spherical cell transition, indicates 218 
that formation of spherical cells in P. aeruginosa does not depend on the acquisition of 219 
chromosomal mutations. Rather, our results suggest that spherical cell formation is an intrinsic 220 
protective response. By undergoing rapid en masse phenotypic transitions between bacillary and 221 
spherical cell morphotypes, the vast majority of the P. aeruginosa population are able to survive 222 
exposure to meropenem and are poised to transition to the bacillary form when antibiotic levels 223 
are reduced.  224 
 225 
Penicillins and carbapenems induce spherical cell-mediated antibiotic tolerance 226 
Having determined that P. aeruginosa PA14 cells quickly convert to a spherical cell morphotype 227 
when treated with meropenem, we were interested to determine whether other cell wall-targeting 228 
antibiotics can elicit a similar response. Interestingly, P. aeruginosa has previously been shown 229 
to induce “spheroplasts” in response to carbenicillin (19), a penicillin derivative, and we reasoned 230 
that these spherical cells could facilitate tolerance to the drug. We found that following treatment 231 
of PA14 with carbenicillin (5x MIC), a large proportion of cells indeed converted to spherical 232 
cells and did so via the same morphological pathway that we observed in response to meropenem 233 
exposure (Fig. 5). In contrast to meropenem, however, some cells became filamentous rather than 234 
converting to the spherical cell state (Fig. 5). While filamentation is a common phenotype 235 
associated with β-lactam treatment in rod-shaped bacteria (3, 20), we found that the P. 236 
aeruginosa filamentous cells arising under these conditions tended to lyse. Live/dead staining 237 
with Syto9 and propidium iodide showed that the filamentous cells stained with propidium iodide 238 
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indicating that they were non-viable (Fig. 5C) whereas the spherical cell morphotypes stained 239 
only with Syto9 and were therefore viable. As was observed after removal of meropenem, the 240 
population of carbenicillin-induced spherical cells rapidly reverted to normal bacillary cells when 241 
resuspended in fresh media lacking the antibiotic (data not shown).  242 
 243 
We also examined the effect of imipenem (5x MIC) on P. aeruginosa PA14 cells. Like 244 
meropenem, imipenem is a carbapenem antibiotic and we found that this also induced a rapid and 245 
reversible transition of the entire cellular population to spherical cells (Fig. S2). Taken together, 246 
these results demonstrate that spherical cell-mediated antibiotic tolerance in P. aeruginosa can 247 
occur in response to β-lactams from at least two classes. 248 
 249 
Meropenem-induced spherical cells are efficiently killed by antimicrobial peptides 250 
Having established that P. aeruginosa cells convert very rapidly and efficiently to cell wall 251 
deficient spherical cells when treated with β-lactam antibiotics, we hypothesized that the 252 
combination of a β-lactam that induces spherical cell formation with a drug that kills spherical 253 
cells could be feasible as a new and effective treatment approach for P. aeruginosa infections. 254 
One class of compounds that we reasoned might exhibit strong spherical cell killing activity were 255 
antimicrobial peptides (AMPs). These compounds function by direct interaction with membrane 256 
lipids and are thought to induce cell death through the formation of pores in the cytoplasmic 257 
membrane (21). Our TEM images show that there are vast stretches of cytoplasmic membrane 258 
exposed on the surface of spherical cells (Fig. 3) which should therefore be much more accessible 259 
to AMPs. Importantly, AMPs tend to have only weak antimicrobial activities against normal 260 
bacillary cells of P. aeruginosa under physiological conditions (22).  261 
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 262 
To test our hypothesis, cultures of P. aeruginosa PA14 were treated with a combination of 263 
meropenem to induce spherical cell formation (at a fixed concentration of 5 μg/mL) and one of 264 
the AMPs LL-37 or nisin (at various concentrations between 0 and 128 μg/mL). After 24 h in the 265 
presence of the drug combinations, viable cell counts were determined by serial dilution and 266 
plating. While meropenem alone produced viable spherical cells, the addition of LL-37 or nisin 267 
markedly reduced viability (Fig. 6A). In fact, at the highest AMP concentration tested (128 268 
μg/mL), viable cell counts were more than 3-4 log lower than those of the meropenem only 269 
control. IC50 values were 16 μg/mL for nisin and 32 μg/mL for LL-37 in combination with 270 
meropenem. The strong bactericidal activity of the meropenem/AMP combinations was further 271 
highlighted by a distinct absence of intact cells under the microscope, replaced with what 272 
appeared to be cellular debris (Fig. 6B-D). Importantly, under our assay conditions the AMPs 273 
alone (LL-37 or nisin) showed no detectable antibacterial ability (Fig. 6E-H) even at the highest 274 
concentration tested (128 μg/mL). This is consistent with the high MIC values recently reported 275 
for LL-37 against PA14 cells under similar conditions (23) (112 – 225 μg/mL). These 276 
observations suggest, as predicted, that AMPs are more effective against spherical cells than 277 
normal bacillary cells, which we further confirmed by demonstrating that the AMPs can 278 
efficiently kill pre-formed P. aeruginosa spherical cells (Fig. S3).  279 
 280 
Finally, time-kill assays were performed with PA14 to examine the rate of meropenem/AMP-281 
induced cell death (Fig. 7A). Both LL-37 and nisin triggered a rapid decline in viability when 282 
administered in combination with meropenem. A 100-fold reduction of viable cell counts relative 283 
to the meropenem only control was observed within just 1 h for LL-37 and 8 h for nisin and by 284 
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24 h viability was reduced by 4-5 log for both AMP/meropenem combinations. Interestingly, the 285 
rapid killing by LL-37 suggests that only a partial transition of the cell to the spherical cell state 286 
is required for the AMP to mediate killing. We confirmed this for LL-37 using time-lapse 287 
microscopy, which showed that the peptide causes the cell to burst at the site of spherical cell 288 
formation (Fig. 7B).  289 
 290 
Discussion 291 
Currently there is a desperate need for innovative approaches to antimicrobial therapy. This stems 292 
from a relentless rise in the emergence of antibiotic resistant bacteria, a lack of new antibiotic 293 
classes in the pharmaceutical pipeline, and greatly reduced investment within the pharmaceutical 294 
sector (24-26). Our data show that it is possible to effectively kill bacteria by turning their own 295 
biological responses against them, namely using drug combinations that induce the cell to 296 
transition to an alternative form then exploit the inherent weaknesses of that form. Drug 297 
combinations are commonly used in medicine to enhance the effectiveness of existing antibiotics 298 
(24), and represent a promising avenue for the development of new treatments (27-29) with 299 
reduced rates of resistance (30). In this study we have shown that combinations of meropenem 300 
with AMPs LL-37 or nisin are potently bactericidal against P. aeruginosa at concentrations 301 
where each drug alone has negligible bactericidal activity. Our findings provide a platform to 302 
identify novel antibacterial drug combinations that induce and target spherical cells in a directed 303 
and cost effective manner. 304 
 305 
Significantly, our observations suggest that the ability to switch between bacillary and spherical 306 
cell morphotypes is a response to stress invoked by exposure to β-lactam antibiotics. Transition 307 
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of P. aeruginosa to the spherical state occurred rapidly in response to β-lactams from the 308 
carbapenem and penicillin classes, and was found to be independent of genetic background. 309 
These results suggest that spherical cell formation may be an intrinsic developmental response of 310 
P. aeruginosa that is induced by antibiotic treatment. Whilst the production of spherical cells by 311 
carbapenems and penicillins has been reported previously (7, 8, 19), our observations show for 312 
the first time that spherical cell formation is reversible and occurs readily under physiological 313 
conditions, indicating that this response may serve as a genuine mechanism of drug tolerance.  314 
 315 
We propose that spherical cell-mediated β-lactam tolerance may underlie many of the 316 
pharmacodynamic challenges associated with β-lactam treatment of P. aeruginosa infections (12-317 
14), at least in the case of carbapenems and penicillins. P. aeruginosa infections are notoriously 318 
difficult to treat and are often chronic or recurrent in nature, particularly in immunocompromised 319 
patients (31). It is tempting to speculate that the transition of P. aeruginosa to a viable alternative 320 
spherical cell morphotype during exposure to β-lactams could lead to prolonged or recurrent 321 
infections by allowing the bacterium to survive in vivo over the course of antibiotic treatment and 322 
then to revert to the bacillary form when antibiotic therapy is ceased .   323 
 324 
Significantly, spherical cell formation may also play an important role in the emergence of β-325 
lactam resistance. Spontaneous β-lactam resistant mutants of P. aeruginosa are known to arise 326 
quite readily in vitro during antibiotic treatment (12, 14). Here we have shown that P. aeruginosa 327 
can undergo en masse transition to cell wall defective spherical cells under these conditions. 328 
While in the spherical form the population would be well poised to acquire β-lactam resistance, 329 
either by mutation or lateral gene transfer (1), which would enable reversion to the bacillary form 330 
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and rapid cell proliferation. Consistent with this idea, early studies on carbenicillin-induced 331 
spheroplasts of P. aeruginosa showed that cells spontaneously reverted to rods after extended 332 
exposure to the drug (5-8 days), and that the MIC of carbenicilin increased as much as 150-fold 333 
following reversion (19, 32). Critically, we now show that a carbapenem in combination with 334 
antimicrobial peptides induces rapid killing of P. aeruginosa cells. This type of approach would 335 
severely limit the potential for acquiring resistance during β-lactam therapy.  336 
 337 
A classic problem in population and evolutionary biology is to understand how a population 338 
copes with environmental changes that challenge survival. Common strategies that enable 339 
survival of antibiotic exposure by bacterial populations include selection of a sub-population that 340 
has a fitness advantage that can arise either through mutation, stochastic phenotypic 341 
heterogeneity or regulated responses (33). Our observations suggest that tolerance to β-lactam 342 
exposure by P. aeruginosa can occur through an adaptive response that involves en masse 343 
phenotypic transitions between bacillary cells and spherical cells with defective cell walls. 344 
Therefore, population-wide morphotype transitions add to the repertoire of strategies that can be 345 
employed by bacteria to survive exposure to β−lactam antibiotics.  346 
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Figure Legends 440 
Fig. 1. P. aeruginosa rapidly converts to spherical cells in response to a β-lactam antibiotic. 441 
PA14 cells cultured in cation-adjusted Mueller Hinton broth (CAMHB) were treated with 442 
meropenem (5x MIC) and visualized by phase-contrast or fluorescence (live/dead) microscopy. 443 
(A-D) Phase-contrast images taken immediately prior to meropenem addition (A) and after 1 h 444 
(B), 4 h (C) and 24 h (D) in the presence of the drug. (E) Proportion of rods, spherical cells and 445 
transitioning cells in the population over time. 200 cells were scored from phase-contrast 446 
micrographs at each time point from 2 experiments. (F-I) Live/dead viability staining of 447 
meropenem-treated cells after 24 h. Cells were grown in CAMHB (F-G) or CAMHB 448 
supplemented with 0.5M sucrose (H-I). Samples were co-stained with SYTO9 (live, green) and 449 
propidium iodide (dead, red) and visualized by phase-contrast (F, H) and wide-field fluorescence 450 
microscopy (G, I). Arrow points to a lysed cell. Scale bars 5 μm.  451 
 452 
Fig. 2. Super resolution 3D-SIM microscopy showing the transition of P. aeruginosa to 453 
meropenem-induced spherical cells. Following treatment with meropenem, PA14 cells were 454 
stained with membrane dye FM1-43 and visualized by 3D-SIM. Images were acquired at 0 h (A), 455 
2 h (B) and 24 h (C) after meropenem addition. Asterisk highlights a developing spherical cell 456 
that is fully surrounded by membrane. Arrow shows a cell at an earlier stage of the transition, 457 
containing a surface bulge that is not yet membrane-enclosed. Scale bars 1 μm. 458 
 459 
Fig. 3. Meropenem-induced spherical cells of P. aeruginosa have a compromised cell 460 
envelope. Transmission electron microscopy (TEM) was performed on thin sections of PA14 461 
cells immediately prior to the addition of meropenem (A, B) and after 24 h in the presence of the 462 
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drug (C, D). Panels B and D are shown at high magnification to illustrate the cell envelope 463 
structure, revealing an intact outer membrane (black arrow) and inner membrane (white arrow) in 464 
the bacillary form (B) and a clearly disrupted outer membrane in the spherical cell (D). Arrow in 465 
C shows a vesicle that appears to have formed from detached outer membrane material. Scale 466 
bars 100 nm.  467 
 468 
Fig. 4. Spherical P. aeruginosa cells rapidly revert to normal rods in the absence of 469 
antibiotic. Meropenem-induced spherical cells of PA14 were resuspened in antibiotic-free media 470 
and visualized by phase-contrast microscopy or 3D-SIM. (A-D) Phase-contrast images taken at 0 471 
h (A), 2 h (B), 6 h (C) and 24 h (D) after removal of meropenem. (E) 3D-SIM images of FM1-43 472 
stained cells captured at various stages in the transition from spherical cell (i) to normal rod (vi). 473 
(F) Proportion of spherical cells, rods and transitioning cells in the population over time. 200 474 
cells were scored from phase-contrast micrographs at each time point from 2 experiments. Scale 475 
bars 5 μm (A-D) or 1 μm (E).  476 
 477 
Fig. 5. Spherical cells induced by carbenicillin. (A-B) 3D-SIM images of PA14 cells stained 478 
with membrane dye FM1-43 after 2 h (A) and 24 h (B) in the presence of carbenicillin. (C) 479 
Live/dead viability staining of carbenicillin-treated cells after 24 h, showing viable spherical cells 480 
and a dead filamentous cell. Cells were co-stained with SYTO9 (live, green) and propidium 481 
iodide (dead, red) and visualized by wide-field flourescence microscopy. (D) Proportion of rods, 482 
spherical cells, transitioning cells and filaments in the population over time. 200 cells were 483 
scored from phase-contrast micrographs at each time point. Scale bars 1 μm (A-B) or 5 μm (C). 484 
 485 
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Fig. 6. AMPs selectively kill meropenem-induced spherical cells of P. aeruginosa. (A) Viable 486 
cell counts after treatment of PA14 for 24 h with a combination of meropenem (5 μg/mL) and 487 
either LL-37 or nisin (0-128 μg/mL). (B-D) Representative phase-contrast images of cells treated 488 
under the same conditions as in A. (B) Meropenem only control (no peptide), showing intact 489 
spherical cells. (C) LL-37 (128 μg/mL) with meropenem. (D) Nisin (128 μg/mL) with 490 
meropenem. Cellular debris can be seen in place of intact cells for both AMP/meropenem 491 
combinations. (E) Viability counts for untreated cells and cells treated with LL-37 or nisin alone 492 
(128 μg/mL). (F-H) Corresponding phase-contrast images. (F) Untreated control, showing 493 
normal rod shaped cells. (G) LL-37. (H) Nisin. Neither AMP alone appears to have any effect on 494 
cellular morphology. Scale bar 5 μm. For (A) and (E) one representative data set is shown from 495 
duplicate (A) or triplicate (E) experiments. Error bars correspond to the standard error of the 496 
mean for triplicate measurements.  497 
 498 
Fig. 7. Meropenem and AMP combinations induce rapid cell death. (A) Time-kill assay. 499 
Viable cell counts were measured at regular intervals after the addition of meropenem (5 μg/mL), 500 
both alone and in combination with LL-37 or nisin (128 μg/mL), to a culture of PA14 cells. One 501 
representative data set from duplicate experiments is shown. Error bars correspond to the 502 
standard error of the mean for triplicate measurements. (C) Time-lapse microscopy capturing the 503 
peptide-mediated death of a developing spherical cell. PA14 cells were treated with meropenem 504 
(5 μg/mL) for 1 h to induce a partial transition to the spherical state. LL-37 (128 μg/mL) was 505 
then added, and phase-contrast images were collected at 2 s intervals over a period of 30 min. In 506 
the example shown, panel i was acquired 13 min after the addition of the peptide, and each 507 
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subsequent image after an additional 2 s. A total of 13 individual cell death events were observed 508 
over four separate experiments. Scale bar 1 μm. 509 







